Preventing hormone-dependent breast cancer in high-risk women

Journal of the National Cancer Institute

Volumn 95, Issue 2, 2003, Pages 91-93

  Vogel, Victor G ^a   Lo, Shelly ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; AGE; AGED; BODY HEIGHT; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HORMONE DEPENDENCE; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; ITALY; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSAL SYNDROME; NULLIPARA; OVARIECTOMY; PREDICTION; PRIORITY JOURNAL; RANDOMIZATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR;

EID: 0037440262     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.2.91     Document Type: Editorial

References (18)

1. Powles T, Eeles R, Ashley S, Easton D. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998;352:98-101.
2. IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817-24.
3. Veronesi U. Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson N, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998;352:93-7.
4. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
5. Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, et al. The Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95:000-00.
6. Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P, and The Italian Tamoxifen Study Group. Tamoxifen for breast cancer among hysterectomised women. Lancet 2002;359:1122-4.
7. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993;15:36-47.
8. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;289:321-33.
9. Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA, for the Multiple Outcomes of Raloxifene Evaluation (MORE) Trial. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 2002;287:216-20.
10. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clinical Breast Cancer 2002;3:153-9.
11. Vogel VG. Why do we still use hormone replacement therapy? Why don't we use it more? J Clin Oncol 2002;20:616-9.
12. Vogel VG. High-risk populations as targets for breast cancer prevention trials. Prev Med 1991;20:86-100.
13. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichouet J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541-8.
14. Gail MH, Brinton LA. Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
15. Vogel VG. Reducing the risk of breast cancer with tamoxifen in women at increased risk. J Clin Oncol 2001;19:87s-92s.
16. Gail, MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-46.
17. Chlebowski R, Col N, Weiner E, Collyar D, Cummings S, Vogel V, et al., for the ASCO Breast Cancer Technology Assessment Working Group. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002;20:3328-43.
18. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9.